PTC Therapeutics Raises $50 Million
PTC Therapeutics Inc., a South Plainfield, N.J.-based drug company focused on post-transcriptional control mechanisms, has raised $50 million in new VC funding. The Column Group and return backer Delphi Ventures co-led the round. Undisclosed new investors were joined by return backers like CSFB Private Equity, HBM BioVentures, Novo A/S and Celgene. PTC previously raised over $143 million in VC funding, and filed for an IPO in 2006 that it later withdrew.
23 December 2009•2 mins read
